伦敦, April 12, 2025 (GLOBE NEWSWIRE) -- Vantage Biosciences，一家推进糖尿病眼疾创新治疗的临床阶段生物技术公司，于今日宣布已在评估 VX-01 的第 2 期临床研究中成功完成首例患者的给药，VX-01 是治疗非增殖性糖尿病视网膜病变 (NPDR) 的一种口服疗法。
Posted: 2025-04-12 10:06:00
Article Tools/Herramientas de artículos
+ Larger Font/Fuente más grande | - Smaller Font/Fuente más pequeñaGlobe NewsWire News Distribution Service
Press Release: Vantage Biosciences 完成口服 VX-01 治疗非增殖性糖尿病视网膜病变第 2 期临床研究首例患者的给药
- Details
- Written by Globe NewsWire Press Releases
- Category: Globe NewsWire News Distribution Service
伦敦, April 12, 2025 (GLOBE NEWSWIRE) -- Vantage Biosciences，一家推进糖尿病眼疾创新治疗的临床阶段生物技术公司，于今日宣布已在评估 VX-01 的第 2 期临床研究中成功完成首例患者的给药，VX-01 是治疗非增殖性糖尿病视网膜病变 (NPDR) 的一种口服疗法。
Posted: 2025-04-12 10:06:00
Listen to this article. Speaker link opens in a new window.
Related Bing News Search Results
Press Release: Vantage Biosciences 完成口服 VX-01 治疗非增殖性糖尿病视网膜病变第 2 期临床研究首例患者的给药 - Newscast
Vantage Biosciences doses first patient in phase 2 study of VX-01, oral therapy for non-proliferative diabetic retinopathy
Fri, 11 Apr 2025 07:41:00 GMT VX01-DR-201, is a phase 2, multi-center, double-masked, randomized, placebo-controlled study in patients with moderate to severe NPDR without center-involved diabetic macular edema (CI-DME).
Related Product Search/Búsqueda de productos relacionados
